（原标题：迈瑞医疗(300760.SZ)发布上半年业绩，归母净利润50.69亿元，下降32.96%） 智通财经APP讯，迈瑞医疗(300760.SZ)发布2025年半年度报告，该公司营业收入为167.43亿元，同比减 少18.45%。归属于上市公司股东的净利润为50.69亿元，同比减少32.96%。归属于上市公司股东的扣除 非经常性损益的净利润为49.49亿元，同比减少32.94%。基本每股收益为4.184元。此外，拟向全体股东 每10股派发现金红利13.10元(含税)。 报告期内，公司国际业务同比增长5.39%，国际业务收入占公司整体收入的比重进一步提升至约50%。 目前业务进度符合公司预期，预计2025年下半年国际业务增长将有所提速，其中国际体外诊断产线有望 实现较快增长。 ...

智通财经APP讯，迈瑞医疗(300760.SZ)披露2025年第三季度主要经营情况，经公司初步测算，公司2025 年第三季度整体营业收入将实现同比正增长，同时延续营业收入金额逐季度环比改善的趋势。其中：国 际市场第三季度同比增长加速，国际体外诊断产线有望实现较快增长;国内市场将明显改善，如期迎来 拐点。 ...

Core Insights - The core viewpoint of the articles highlights the strong financial performance and growth prospects of Mindray Medical, driven by both domestic and international business segments, alongside significant investments in research and development. Financial Performance - In the first half of 2025, Mindray Medical achieved operating revenue of 16.743 billion yuan and a net profit attributable to shareholders of 5.069 billion yuan, with net cash flow from operating activities reaching 3.922 billion yuan [1] - The company announced a second interim dividend plan of 1.31 yuan per share (before tax), totaling 1.588 billion yuan, bringing the cumulative cash dividend for 2025 to 3.298 billion yuan, which is 65.06% of the net profit for the period [1] - Since its IPO, the company has consistently paid dividends for seven years, with a total dividend payout expected to reach 35.7 billion yuan, six times the IPO fundraising amount of 5.934 billion yuan [1] Business Segments - International business revenue reached 8.332 billion yuan, accounting for 50% of total revenue, with significant growth in developing countries [1][3] - Domestic business revenue was 8.411 billion yuan, impacted by delays in medical equipment bidding, but is expected to recover in the third quarter of 2025 [2][6] - The in-vitro diagnostics segment generated 6.424 billion yuan, with international business showing double-digit growth, particularly in the international chemiluminescence sector, which grew over 20% [4] Research and Development - Mindray Medical maintained high R&D investment of 1.777 billion yuan, representing 10.61% of revenue, enhancing its technological innovation capabilities [2][8] - The company has filed a total of 12,240 patents, with 8,818 being invention patents, and has authorized 6,126 patents, including 3,085 invention patents [2] Market Position and Growth Prospects - The company is well-positioned in the global medical device market, which is projected to grow from $623 billion in 2024 to $869.7 billion by 2030, with a compound annual growth rate of 5.7% [5] - Mindray Medical's life information and support business achieved revenue of 5.479 billion yuan, with international business contributing 67% of this segment [5] - The company is focusing on high-potential areas such as minimally invasive surgery, with significant growth expected in this segment due to the introduction of innovative products [7] Strategic Initiatives - Mindray Medical is building a smart medical ecosystem integrating "equipment + IT + AI," enhancing its competitive edge in both domestic and international markets [9] - The company is expanding its local production capabilities in 14 countries, with 11 projects already in production, primarily for in-vitro diagnostic products [4] - The company aims to leverage its unique competitive advantages in the increasingly centralized and compliant bidding process to enhance its market share in the in-vitro diagnostics sector [7]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, alongside a robust commitment to R&D and international expansion [1][2][3]. Financial Performance - The company achieved operating revenue of 16.743 billion yuan and a net profit of 5.069 billion yuan for the first half of 2025 [1]. - The net cash flow from operating activities was 3.922 billion yuan [1]. - The total cash dividend for 2025 is projected to reach 3.298 billion yuan, representing 65.06% of the net profit for the period [1]. International Business Growth - International business revenue reached 8.332 billion yuan, accounting for 50% of total revenue, with a year-on-year growth of 5.39% [3]. - Revenue from developing countries was 5.435 billion yuan, maintaining a two-thirds share of international business revenue [3]. - The company expects accelerated growth in international business in the second half of 2025, driven by local platform development and high-end customer acquisition [3]. Domestic Market Dynamics - Domestic business revenue was 8.411 billion yuan, impacted by delayed medical equipment tenders from the previous year, but is expected to recover in the third quarter of 2025 [2][6]. - The company anticipates a significant improvement in domestic market conditions due to the revival of medical equipment tender activities [6]. R&D Investment - The company maintained high R&D investment of 1.777 billion yuan, representing 10.61% of total revenue for the first half of 2025 [2][8]. - The company has filed a total of 12,240 patents, with 8,818 being invention patents, indicating a strong focus on innovation [2]. Product Line and Market Position - The company has a comprehensive product line across three main business areas: in vitro diagnostics, life information and support, and medical imaging [3][4]. - The in vitro diagnostics segment generated revenue of 6.424 billion yuan, with international business showing double-digit growth [4]. - The life information and support segment achieved revenue of 5.479 billion yuan, with international business contributing 67% of the total [5]. Future Outlook - The global medical device market is projected to grow from $623 billion in 2024 to $869.7 billion by 2030, with a compound annual growth rate of 5.7% [5]. - The company is well-positioned to capitalize on market opportunities through innovation and strategic expansion [10].

Core Insights - Mindray Medical reported a revenue of 16.743 billion yuan and a net profit attributable to shareholders of 5.069 billion yuan for the first half of 2025 [1] Group 1: International Business Performance - The company's international business generated revenue of 8.332 billion yuan, accounting for 50% of total revenue, with rapid growth in developing countries [1] - Mindray maintains a top-three market share globally in products such as monitors, anesthesia machines, ventilators, defibrillators, blood cell analyzers, and ultrasound products [1] - The company anticipates accelerated growth in international business in the second half of 2025, particularly in the in-vitro diagnostics segment [1] Group 2: Domestic Business Outlook - With the recovery of medical equipment bidding activities in the first half of 2025, the domestic market is expected to see a turning point in the third quarter [1] - Preliminary estimates suggest that the company's overall revenue will achieve year-on-year growth in the third quarter, continuing a trend of quarter-on-quarter improvement in revenue [1]

（文章来源：新华财经） 迈瑞医疗公告，公司2025年上半年实现营业收入167.43亿元，同比下降18.45%；归属于上市公司股东的 净利润为50.69亿元，同比下降32.96%；公司拟向全体股东每10股派发现金红利13.10元（含税）。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，迈瑞医疗发布公告称，2025年上半年实现营业 收入167.43亿元，同比下降18.45%；归属于上市公司股东的净利润为50.69亿元，同比下降32.96%；归 属于上市公司股东的扣除非经常性损益的净利润为49.49亿元，同比下降32.94%。 ...

深圳迈瑞生物医疗电子股份有限公司 信息披露暂缓和豁免管理制度 第一章 总则 第二章 暂缓、豁免披露信息的范围 第五条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息涉及国家秘 密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下统称 1 第一条 为规范深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资者合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披 露管理办法》《上市公司信息披露暂缓与豁免管理规定》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等法律、法规、规范性文件以及《深圳迈瑞生物医疗 电子股份有限公司章程》（以下简称"《公司章程》"）等有关规定，结合公司 的实际情况，特制定本制度。 第二条 公司和其他信息披露义务人按照相关法律法规及深圳证券交易所（以下简称 "深交所"）相关业务规则的规定，暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和深交所规定或者要求披露的 内容，适用本制度。 第 ...

Financial Performance - Total revenue for the first half of 2025 reached 167.4 billion CNY, with a net profit of 50.7 billion CNY [1] - Total assets amounted to 587.7 billion CNY, and net assets were 440.2 billion CNY [1] - The company anticipates positive year-on-year revenue growth in Q3 2025, continuing a trend of quarterly improvement [1] Shareholder Returns - The company announced a cash dividend of 17.1 billion CNY (before tax) for the first mid-term distribution in April 2025 [1] - A second mid-term cash dividend of 15.9 billion CNY (before tax) is planned for August 2025 [1] - The annual profit distribution will be at least 65% of the distributable profit [1] Business Segments In Vitro Diagnostics - Revenue from in vitro diagnostics reached 64.2 billion CNY, accounting for 38.4% of total revenue, with a double-digit year-on-year growth [1] - International chemical luminescence business grew by over 20% year-on-year [1] - The company sold 13 sets of the MT 8000 fully automated laboratory intelligent assembly line, with a total of 15 sets sold [1] Medical Imaging - Revenue from medical imaging was 33.1 billion CNY, representing 19.8% of total revenue [1] - The company has established a strong presence in the international market, with significant growth expected in Q3 2025 [3] Life Information and Support - Revenue from life information and support reached 54.8 billion CNY, making up 32.7% of total revenue [1] R&D and Innovation - R&D investment for the reporting period was 17.8 billion CNY, constituting 10.6% of total revenue [3] - The company has applied for a total of 12,240 patents, with 6,126 granted, including 3,085 invention patents [3] Market Expansion - The "瑞检生态" smart laboratory solution has been installed in nearly 800 hospitals, with 80% being tertiary hospitals [4] - The company has expanded its international footprint, with installations in countries like Jordan, Indonesia, Thailand, and Romania [7] Sustainable Development - The company maintained an MSCI ESG rating of AA for the third consecutive year and was included in the S&P Global Sustainable Development Yearbook (China Edition) [15] - Over 230,000 individuals participated in emergency training, with 9,008 people trained in 201 events [15]

人民财讯8月27日电，迈瑞医疗（300760）8月27日晚间披露半年报，2025年上半年，公司实现营业收入 167.43亿元，同比下降18.45%；归母净利润50.69亿元，同比下降32.96%；基本每股收益4.184元；拟每 10股派发现金红利13.1元(含税)。经公司初步测算，第三季度整体营业收入将实现同比正增长，同时延 续营业收入金额逐季度环比改善的趋势。其中：国际市场第三季度同比增长加速，国际体外诊断产线有 望实现较快增长；国内市场将明显改善，如期迎来拐点。 ...